Biotech Tracker: Zenapax (Daclizumab) for Asthma - USA Voicemail and Fax:- (+1) 415 680 2472 San Francisco UK Tel:- (+44) 1300 321501 - who , what , where , when and why biotechnology will impact on our lives- Biotech Tracker: Zenapax (Daclizumab) for Asthma Biotech Tracker: Zenapax (Daclizumab) for Asthma BioPortfolio, biotechnology, pharmaceuticals, medicine, drugs, healthcare, biotechnology jobs, biotech...
BioPortfolio BioNews (News & Press Releases) March 2004 in Japan Lynx and Solexa Jointly Acquire DNA Technology Assets Researchers report the efficacy of the bisphosphonate, YM529 in preclinical rheumatoid arthritis studies Agilent Technologies Upgrades Software for Mass Spectrometry-Based Proteomics Research Researchers report that controlling intracellular calcium levels may offer a new dual approach to hypertension and diabetes CHI's...
BioPortfolio Client Press Releases Site Map in Japan Lynx and Solexa Jointly Acquire DNA Technology Assets Researchers report the efficacy of the bisphosphonate, YM529 in preclinical rheumatoid arthritis studies Agilent Technologies Upgrades Software for Mass Spectrometry-Based Proteomics Research Researchers report that controlling intracellular calcium levels may offer a new dual approach to hypertension and diabetes CHI's...
Another Disappointment for PDLI - - - - BioNews BioWeb Companies Products BioReports - - - - - Another Disappointment for PDLI Protein Design Labs' (NASDAQ: PDLI) phase II investigations of Zenapax (daclizumab) have failed to meet their primary therapeutic goal in the treatment of patients with moderate-to-severe psoriasis.
BiotechTracker - PDLI Shows Some Guts - - - - BioNews BioWeb Companies Products BioReports - - - - - - BiotechTracker - PDLI Shows Some Guts- May 20, 2003 Protein Design Labs’ (NASDAQ: PDLI) inflammatory bowel disease franchise – Nuvion, daclizumab, and HuZAF – has made small, but significant, steps forward.- Nuvion Nuvion (visilizumab) is an anti-CD3 antibody.
Database D D - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
Database Z Z - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Therapeutic Biological Approvals Karl Thomae GmbH Birkendorfter Strasse 65 88397 Biberach/Riss GERMANY License 1199 08/20/1996 Xigris Drotrecogin alfa (activated) Reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (e.g., as determined by APACHE II) 125029/0 Eli Lilly & Co Lilly Corporate Center Indianapolis, IN 46285 License 1611...
CDER: Previous News Items 2003 FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - Previous News Items 2003 Previous News Items 2004 Previous News Items 2002 December 30, 2003 The prescribing information for Topamax (topiramate/topiramate capsules) has been revised to include a warning that Topamax causes hyperchloremic, non-anion gap metabolic acidosis (decreased serum...
Roche Selected Products Therapeutic Area Product Brand Name / Main Indication Indication Anesthesia and sedation Dormicum/Versed midazolam Cancer Furtulon doxifluridine Cancer of the colon Herceptin trastuzumab Breast cancer Kytril granisetron hydrochloride Cancer Mabthera/Rituxan rituximab Non-Hodgkin's lymphoma Roferon-A interferon alfa-2a Cancer Xeloda capecitabine Breast cancer Cardiovascular diseases...
Roche Media News 1997 Dec, 16 Roche is Further Strengthening its Position in Asia: 6th Joint Venture in China Signed - Dec, 11 First Genetically Engineered Drug To Reduce Risk Of Kidney Rejection Receives FDA Marketing Clearance Unique mechanism of action of Zenapax ® (Daclizumab) improves success rate of kidney transplants without increasing side effects - Nov, 28 MabThera®: Hope for...
Roche Media News 1999 Dec, 17 Roche to take part in Expo.02 - Dec, 6 New member to join Roche Executive Committee - Dec, 6 Roche to spin off fragrances and flavours division - Sharp focus on healthcare business - Nov, 3 Class action suits with US bulk vitamin customers settled - Oct, 28 Roche receives FDA approval for Tamiflu™ - Oct, 21 Roche prices the successful offering of Genentech shares - Oct,...
Pharmaceutical Research and Manufacturers of America - Protein Design Labs Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes humanized anti-IL-4 antibody none / none Asthma Protein Design Labs Fremont, CA Phase II - Nuvion none / SMART anti-CD3 Graft v
Pharmaceutical Research and Manufacturers of America - Uveitis Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Avonex Avonex / interferon beta-1a Amyotrophic Lateral Sclerosis (Lou Gehrig's) Chronic Inflammatory Demyelinating Polyneuropathy Inclusion Body...
Pharmaceutical Research and Manufacturers of America - Multiple Sclerosis Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes 683699 (dual alpha 4 integrin antaginist) none / none Multiple Sclerosis GlaxoSmithKline Research Triangle Park, NC Phase I - AnergiX-MS...
Pharmaceutical Research and Manufacturers of America - Type 1 Diabetes Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes NBI-6024 none / NBI-6024 Type 1 Diabetes Neurocrine Biosciences San Diego, CA Phase II type 1 - Symlyn none / pramlintide acetate Insulin...
Roche Investor Updates 1999 - - - - - - Dec, 6 New member to join Roche Executive Committee - Dec, 6 Roche to spin off fragrances and flavours division - Sharp focus on healthcare business - Nov, 3 Class action suits with US bulk vitamin customers settled - Oct, 28 Roche receives FDA approval for Tamiflu™ - Oct, 21 Roche prices the successful offering of Genentech shares - Oct, 20 Roche determines not to...
Approved Biotechnology Drugs, 2002 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
Daclizumab - Product Approval Information - Licensing Action Hoffmann-La Roche Inc., Nutley, New Jersey is hereby authorized to manufacture and ship for sale, barter, or exchange in interstate and foreign commerce Daclizumab under Department of Health and Human Services Biologics License NoZenapax, and will be marketed in 5 ml single-use vials containing...
Daclizumab - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Daclizumab Product Approval Information - Licensing Action Proper name: Daclizumab Tradename: Zenapax Manufacturer: Hoffman-La Roche Inc, Nutley, NJ, License #0136 Revised Package Insert: Include pediatric use and update the Clinical Pharmacology, Clinical Studies, and...
Daclizumab - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - Daclizumab Product Approval Information - Licensing Action Proper name: Daclizumab Tradename: Zenapax Manufacturer: Hoffman-La Roche Inc, Nutley, NJ, License #0136 Indication for Use: Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used...
drugname - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Talk Papers Therapeutic Biological Products FDA Approves First Treatment for Genetic Metabolic Disorder Including Hurler Disorder - 4/30/2003 FDA Approves First Treatment for Fabry Disease - 4/24/2003 FDA Statement on Counterfeit Procrit - 3/11/2003 FDA Approves First Biologic Therapy for...
http://www.easy.no/affitech/pdf/das1.pdf page 2
duplicates:http://www.iscpubs.com/articles/abl/b0002das.pdf
B.pg 4,6/Das-L/O page 1
author: Rachel Domack
duplicates:http://www.iscpubs.com/articles/abl/b0305das.pdf
Prescription Drug User Fee Act - User Fee Billable Therapeutic Products: Approved Under Section 351 of the PHS Act IU/mL Corixa Corp License 1614 Bexxar Tositumomab and Iodine I-131 Tositumomab 125011/0 6/27/2003 Therapeutic Regimen Cytogen Corp License 1164 ProstaScint Capromab Pendetide 103608/0 10/28/1996 0.5 mg/mL Elan Pharmaceuticals License 1579 MYOBLOC Botulinum Toxin Type B 103846/0 12/8/2000 5,000 IU/mL Eli Lilly & Company License 1611 Xigris Drotrecogin alfa (Activated) 125029/0 11/21...
